aTyr Pharma updates timing for Phase 3 efzofitimod study response
aTyr Pharma said it will provide an update on the timing of the regulatory response for its planned Phase 3 study of efzofitimod in pulmonary sarcoidosis.
Story updates
08:40:32 PM UTC
SquawkNews
Atyr Pharma Provides Update On Timing Of Regulatory Response For Planned Phase 3 Study Of Efzofitimod In Pulmonary Sarcoidosis
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.